Conclusion
There is a clearly defined pathway to developing and evaluating complex
interventions; however, significant variation exists in the extent to
which the pathway is followed. Within the pathway, there are
inconsistencies of interpretation, for example the definition of an
acceptable primary outcome. There is a need for the deprescribing
community to address the inconsistencies and then follow the agreed
pathway from defining the target deprescribing behaviour through to
evaluating intervention fidelity alongside effectiveness.